Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Blinded, Cross-Over Study to Evaluate the Safety and Efficacy of ARD-501 in Patients With Autism Spectrum Disorder

NCT06126653 is registered in ClinicalTrials.gov with Aardvark Therapeutics, Inc. as lead sponsor.

NCT NCT06126653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06126653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Blinded, Cross-Over Study to Evaluate the Safety and Efficacy of ARD-501 in Patients With Autism Spectrum Disorder
Lead sponsor
Aardvark Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2024
Completion date
January 13, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder